Paul Jank

Has grant

Head of Translational Research Laboratory

Country flagGermany

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Paul Jank is the Head of the Translational Research Laboratory at Universitätsklinikum Marburg Pathologie in Germany. His research primarily focuses on breast cancer, colorectal carcinomas, and the molecular mechanisms underlying tumor behavior and response to therapies. Recent publications include studies on PIK3CA mutations in breast cancer and the diagnostic potential of insulinoma-associated protein 1 in colorectal cancer. He also investigates therapeutic targets and signaling pathways in circulating tumor cells and has developed new models for evaluating cancer treatments.

Recent Grants

Grant: Close

Identification of new prognostic tissue-based spatial biomarker profiles and quality-of-life aspects for patients with invasive-lobular breast cancer (ILC)

Open Date:

Close Date:

Articles (10)

Year:

2024

Year:

2023

Complementary to synaptophysin and chromogranin A, insulinoma‐associated protein 1 (INSM1) has emerged as a sensitive marker for the diagnosis of neuroendocrine neoplasms. Since there are no comparative data regarding INSM1 expression in conventional colorectal adenocarcinomas (CRCs) and colorectal mixed adenoneuroendocrine carcinomas/neuroendocrine carcinomas (MANECs/NECs), we examined INSM1 in a large cohort of conventional CRCs and MANECs/NECs. In conventional CRC, we put a special focus on conventional CRC with diffuse expression of synaptophysin, which carry the risk of being misinterpreted as a MANEC or a NEC. We investigated INSM1 according to the immunoreactive score in our main cohort of 1,033 conventional CRCs and 21 MANECs/NECs in comparison to the expression of synaptophysin and chromogranin A and correlated the results with clinicopathological parameters and patient survival. All MANECs/NECs expressed INSM1, usually showing high or moderate expression (57% high, 34% moderate, and 9% low), which distinguished them from conventional CRCs, which were usually INSM1 negative or low, even if they diffusely expressed synaptophysin. High expression of INSM1 was not observed in conventional CRCs. Chromogranin A was negative/low in most conventional CRCs (99%), but also in most MANECs/NECs (66%). Comparable results were observed in our independent validation cohorts of conventional CRC ( n = 274) and MANEC/NEC ( n = 19). Similar to synaptophysin, INSM1 expression had no prognostic relevance in conventional CRCs, while true MANEC/NEC showed a highly impaired survival in univariate and multivariate analyses (e.g. disease‐specific survival: p < 0.001). MANECs/NECs are a highly aggressive variant of colorectal cancer, which must be reliably identified. High expression of INSM1 distinguishes MANEC/NEC from conventional CRCs with diffuse expression of the standard neuroendocrine marker synaptophysin, which do not share the same dismal prognosis. Therefore, high INSM1 expression is a highly specific/sensitive marker that is supportive for the diagnosis of true colorectal MANEC/NEC.

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (10)

Anja E. Hauser

-

GERMANY
View details

Konrad Klinghammer

charité university hospital

GERMANY
View details

Juliana Gonçalves

Technical University of Munich

GERMANY
View details

Christine Solbach

Goethe University Frankfurt

GERMANY
View details

Judith Lea Lindner

-

GERMANY
View details

Moritz Jesinghaus

-

GERMANY
View details

Kristina Schwamborn

Technical University of Munich

GERMANY
View details

Thomas Karn

Goethe University Frankfurt

GERMANY
View details

Ingeborg Tinhofer-Keilholz

Charité - Universitätsmedizin Berlin

GERMANY
View details

Andreas H. Mahnken

University Hospital

GERMANY
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.